公开(公告)号：US20240415788A1

公开(公告)日：2024-12-19

申请号：US18781933

申请日：2024-07-23

Applicant: PhotoPharmics, Inc.

Inventor： Gregory Lynn Willis

IPC: A61K31/13 ,  A61K9/00 ,  A61K31/165 ,  A61K31/4515 ,  A61K31/454 ,  A61K31/5415

Abstract: A method for the treatment and/or prophylaxis of a neurological and/or neuropsychiatric disorder associated with altered dopamine function comprising administering to the eye of a patient in need thereof an effective amount of an agent that modulates neurotransmitter production or function.

公开(公告)号：US20140088439A1

公开(公告)日：2014-03-27

申请号：US14094312

申请日：2013-12-02

Applicant: Photopharmics, Inc.

Inventor： Kent W. Savage ,  Daniel N. Adams ,  Gregory Lynn Willis

IPC: A61N5/06 ,  A61B5/00

CPC classification number: A61N5/0613 ,  A61B5/0059 ,  A61N5/0622 ,  A61N2005/0663

Abstract: Light therapy apparatuses are configured to expose a subject to light that is tailored to address and/or diagnose at least one motor-related neurological condition. Blue-green light and green light are useful for treating motor-related neurological conditions or their symptoms. Deep red light and near infrared radiation may facilitate the repair of retinal cells and/or neurons that may be responsible for motor-related neurological conditions. Amber, orange and red light enable the early diagnosis of motor-related neurological conditions.

Abstract translation: 光治疗装置被配置为将受试者暴露于被定制以解决和/或诊断至少一个运动相关神经病症的光。 蓝绿光和绿光可用于治疗与运动有关的神经病症或其症状。 深红光和近红外辐射可能有助于修复视网膜细胞和/或神经元，这些细胞和/或神经元可能是导致与运动有关的神经病症的原因。 琥珀色，橙色和红色光可以早期诊断与运动有关的神经病症。

公开(公告)号：US12042471B2

公开(公告)日：2024-07-23

申请号：US15794886

申请日：2017-10-26

Applicant: PhotoPharmics, Inc.

Inventor： Gregory Lynn Willis

IPC: A61K31/13 ,  A61K9/00 ,  A61K9/48 ,  A61K9/51 ,  A61K31/165 ,  A61K31/4515 ,  A61K31/454 ,  A61K31/5415 ,  A61P25/16

CPC classification number: A61K31/13 ,  A61K9/0048 ,  A61K31/165 ,  A61K31/4515 ,  A61K31/454 ,  A61K31/5415 ,  A61K9/0051

Abstract: A method for the treatment and/or prophylaxis of a neurological and/or neuropsychiatric disorder associated with altered dopamine function comprising administering to the eye of a patient in need thereof an effective amount of an agent that modulates neurotransmitter production or function.

公开(公告)号：US20220087602A1

公开(公告)日：2022-03-24

申请号：US17544850

申请日：2021-12-07

Applicant: PhotoPharmics, Inc.

Inventor： Gregory Lynn Willis

IPC: A61B5/00 ,  A61N5/06 ,  A61M21/00

Abstract: Methods for preventing or treating motor-related neurological conditions include using ocular light therapy in connection with a conventional therapy for a motor-related neurological condition, such as a drug regimen, to adjust levels of melatonin and/or dopamine in the body of a subject. The ocular light therapy may include elevated levels of blue-green light or green light (e.g., light within a wavelength range of 460 nm to 570 nm, 490 nm to 570 nm, about 520 nm to 570 nm, etc.). The ocular light therapy may also include reduced levels of amber, orange and/or red light. Methods for diagnosing motor-related neurological conditions include use of ocular light therapy to cause a subject to temporarily exhibit one or more symptoms of any motor-related neurological condition to which the subject is predisposed, or which the subject may already be experiencing. A temporary increase in such symptoms may be effected by ocular administration of light including increased amounts of amber, orange and/or red light.

公开(公告)号：US11191478B2

公开(公告)日：2021-12-07

申请号：US14094510

申请日：2013-12-02

Applicant: PhotoPharmics, Inc.

Inventor： Gregory Lynn Willis

IPC: A61B5/00 ,  A61N5/06 ,  A61M21/00 ,  A61B5/11 ,  A61B5/16 ,  G06K9/00

Abstract: Methods for preventing or treating motor-related neurological conditions include using ocular light therapy in connection with a conventional therapy for a motor-related neurological condition, such as a drug regimen, to adjust levels of melatonin and/or dopamine in the body of a subject. The ocular light therapy may include elevated levels of blue-green light or green light (e.g., light within a wavelength range of 460 nm to 570 nm, 490 nm to 570 nm, about 520 nm to 570 nm, etc.). The ocular light therapy may also include reduced levels of amber, orange and/or red light. Methods for diagnosing motor-related neurological conditions include ocular administration of increased amounts of amber, orange and/or red light to cause a subject to temporarily exhibit one or more symptoms of any motor-related neurological condition to which the subject is predisposed, or which the subject may already be experiencing.